Phase 2 Clinical Trial of GH001 in Postpartum Depression

Inclusion Criteria:

• Is female and in the age range between 18 and 45 years (inclusive) at screening.

• Has a body mass index (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) atscreening.

• Meets the trial criteria for PPD as assessed by a trial psychiatrist or registeredclinical psychologist.

Exclusion Criteria:

• Has one or more first or second degree relatives with a current or prior diagnosisof bipolar disorder, psychotic disorder or other mood disorder (including MDD) withpsychotic features.

• Current pregnancy resulting in termination, still-birth, pre-term delivery (beforeweek complete gestational week 37), need for intensive care therapy of mother orchild, or adoption of child away from patient.

• Has taken prohibited medication or prohibited dietary supplements within thespecified timeframe prior to dosing.

• Has previously experienced a significant adverse reaction to a hallucinogenic orpsychedelic drug according to the investigator's judgment.

• Has a clinically significant abnormality in physical examination, vital signs, ECG,or clinical laboratory parameters which renders the patient unsuitable for the trialaccording to the investigator's judgment.

• Patient who has a positive pregnancy test at screening or on the pretest day, ispregnant, or plans to become pregnant during the course of the trial and up to 90days after GH001 dosing.